Results 21 to 30 of about 2,377 (150)

Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis [PDF]

Frontiers in Immunology
BackgroundRelapsing-Remitting Multiple Sclerosis (RRMS) is a chronic inflammatory demyelinating disease affecting the central nervous system, characterized by complex pathogenesis and increasing annual incidence rates.
Yonghong Zhao, Bokun Chen, Xiaojuan Zhao, Ruimeng Yang, Wenjuan He, Dan Li, Qian Sun, Jiaxi Zhang, Xiuju Liu   +8 more
doaj   +2 more sources

Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking [PDF]

Schizophrenia
The treatment of cognitive impairment in schizophrenia is an unaddressed need due to the absence of novel treatments. Recent studies demonstrated that fingolimod and siponimod have neuroprotective effects in several neuropsychiatric disorders; however ...
Chao Li, Chuanjun Zhuo, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang, Lina Wang   +8 more
doaj   +2 more sources

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action

Cells, 2019
Multiple sclerosis (MS) is a neuroinflammatory disorder of the central nervous system (CNS), and represents one of the main causes of disability in young adults.
Markus Kipp, Newshan Behrangi
exaly   +3 more sources

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis. [PDF]

, 2022
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). Although immune modulation and suppression are effective during relapsing-remitting MS, secondary progressive MS (SPMS) requires neuroregenerative therapeutic options ...
Bigaud, Marc, Michael Enders, Christopher Kapitza, Marc Bigaud, Kirchner, Philipp, Kuerten, Stefanie, Ekici, Arif, Enders, Michael, Kapitza, Christopher, Philipp Kirchner, Wörl, Jürgen, Stefanie Kuerten, Arif Ekici, Jürgen Wörl, Alicia Weier, Weier, Alicia   +15 more
core   +3 more sources

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis [PDF]

, 2022
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5) modulator approved in the United States and the European Union as an oral treatment for adults with relapsing forms of multiple sclerosis (RMS), including active ...
Cree, Bruce AC, Benedict, Ralph H. B., Cree, Bruce A. C., Chun, Jerold, Hua, Le H, Benedict, Ralph HB, DeLuca, John, Cohan, Stanley L, Cohan, Stanley L., Hua, Le H.   +9 more
core   +3 more sources

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials

Frontiers in Pharmacology, 2022
Objectives: This study aimed to investigate the pharmacokinetic characteristics of siponimod in healthy volunteers and patients with MS based on aggregated data from published clinical trials, and to explore the factors influencing siponimod exposure ...
Chen Chaoyang, Chen Chaoyang, Dong Xiu, Dong Xiu, Wei Ran, Ma Lingyun, Zhao Simiao, Li Ruoming, Li Ruoming, Zhang Enyao, Zhang Enyao, Zhou Ying, Zhou Ying, Cui Yimin, Cui Yimin, Cui Yimin, Liu Zhenming, Liu Zhenming   +17 more
doaj   +1 more source

Protektive Effekte von Siponimod in präklinischen Multiple Sklerose Tiermodellen [PDF]

, 2023
Diese Studie untersucht die Auswirkungen von Siponimod, einem selektiven Sphingosin-1-Phosphat-Rezeptor-Modulator der nächsten Generation, in experimentellen Tiermodellen (Cuprizone Modell un Cup-EAE Modell) der MS.
Winzinger, Tudor (gnd: 1353548112)
core   +1 more source

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review

BMC Neurology, 2023
Background As a modulator of the sphingosine 1-phosphate receptor, siponimod is administered as a therapeutic intervention for multiple sclerosis. A previous phase 3 study first reported siponimod-associated macular edema.
Qingsheng Li, Li-Jun Jing, Yanfei Li, Yanjie Jia   +3 more
doaj   +1 more source

Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma

Neural Regeneration Research, 2023
Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, Roshana Vander Wall, Rashi Rajput, Kanishka Pushpitha, Samridhi Sharma, Mehdi Mirzaei, Alexander Klistorner, Stuart L Graham   +9 more
doaj   +1 more source

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy

PLoS ONE, 2022
Background Siponimod is an effective treatment for patients with secondary progressive multiple sclerosis (SPMS), with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, however there is a
Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, Mihaela Nica, Daniela Ritrovato, Lorenzo Giovanni Mantovani   +5 more
doaj   +2 more sources